Earnings
Home›Earnings›Previews›Johnson & Johnson posts growth as Stelara decline is o…
Johnson & Johnson posts growth as Stelara decline is offset
The company said it lifted its adjusted EPS outlook to $11.68 at the midpoint after quarterly sales rose to $16.38 billion.
Johnson & Johnson and Thermo Fisher are being weighed against each other by investors focused on long-term healthcare growth, with Johnson & Johnson’s quarter highlighting resilience across its pharmaceutical and medical technology businesses, according to an analysis published by Yahoo Finance. Johnson & Johnson’s pharmaceutical segment was described as a key driver of its results, with quarterly sales of $16.38 billion, ahead of the $16.1 billion estimate cited in the article. The company also raised its annual sales outlook to around $101.1 billion at the midpoint, up from $100.8 billion previously, and lifted its adjusted earnings per share forecast to $11.68 at the midpoint, from $11.55 previously. The piece notes that Johnson & Johnson is offsetting a major patent cliff, with Stelara sales falling more than 55% in the quarter to $740 million due to patent loss. Even so, it pointed to gains in newer immunology and cancer therapies, including Tremfya sales rising 72.5% to $2 billion versus the $1.74 billion estimate mentioned in the article. By contrast, the article frames Thermo Fisher’s outlook as more dependent on a recovery in life sciences spending after several difficult years, setting up a comparison between diversification-led growth at Johnson & Johnson and cycle-linked improvement at Thermo Fisher, though the provided text cuts off before detailing Thermo Fisher’s figures.